Individualized Starting Dose of Niraparib Is Recommended in First-Line Maintenance Setting in Recurrent Ovarian Cancer
In the PRIMA study, patients with recurrent ovarian cancer receiving maintenance therapy with an individualized dose of niraparib had similar efficacy compared with placebo as patients receiving a fixed dose of niraparib while experiencing half as many thrombocytopenic events.
In a pooled analysis of 2 randomized trials of rucaparib for the treatment of patients with recurrent high-grade ovarian cancer, deleterious BRCA mutations were identified in 71% of patients with responses lasting at least 1 year but in only 52% of short-term responders.
Finding a Pathogenic Mutation on Genetic Testing Does Not Add to Stress or Anxiety in Women with Newly Diagnosed Ovarian Cancer
In a study of 76 English-speaking women with newly diagnosed ovarian cancer who underwent genetic testing, those found to have a pathogenic mutation did not report increased levels of stress, anxiety, or depression compared with pre-genetic testing. Those testing negative for mutations saw their posttest anxiety levels decline.
Rucaparib As Maintenance Therapy Delays Progression in Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Niraparib plus Bevacizumab Combination Leads to Improved PFS Without Cumulative Toxicity in Advanced Ovarian Cancer
Adding Olaparib to Bevacizumab as Maintenance Extends PFS in Newly Diagnosed Advanced Ovarian Cancer
PARP Inhibitors in Ovarian Cancer: Choice May Depend on Treatment Setting, Mutation Status, and Side-Effect Profile
Time to First Subsequent Therapy Longer in Patients with Advanced Ovarian Cancer Who Are Treated with Niraparib
The phase 3 PRIMA clinical trial demonstrated that time to first subsequent therapy was 6.6 months longer in the niraparib arm versus the placebo arm, an advantage that was maintained regardless of homologous recombination deficiency status, and the risk for second disease progression was also numerically lower in niraparib-treated patients.
Improvement in progression-free survival observed in the PRIMA clinical trial results in FDA approval of an additional indication for niraparib as first-line maintenance treatment of all patients with advanced ovarian cancer whose disease has had a complete or partial response to first-line platinum-based chemotherapy.
Page 2 of 6
Results 11 - 20 of 51
Results 11 - 20 of 51